Brief: Us FDA Approves Tecentriq With Chemotherapy For Stage III DMMR Colon Cancer
08/10/2026 20:10
BRIEF-Us FDA Approves Tecentriq With Chemotherapy For Stage III DMMR Colon Cancer Oct 8 (Reuters) - US FDA:
US FDA - APPROVES TECENTRIQ WITH CHEMOTHERAPY FOR STAGE III DMMR COLON CANCER
US FDA: APPROVES ATEZOLIZUMAB & HYALURONIDASE-TQJS IN COMBINATION WITH FLUOROPYRIMIDINE & OXALIPLATIN FOR STAGE III DMMR COLON CANCER - WEBSITE
Further company coverage: ROPC.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey